Vincere Biosciences

vìncere (Latin): to win, to conquer

Deficient mitophagy contributes to Parkinson's disease and aging itself.

Vincere's small molecules increase mitophagy and have potential to be the first ever medicines to slow or stop Parkinson's disease and other age-related diseases.

To develop these small molecules we have raised equity and grant funding, including research support from expert agencies such as the Michael J. Fox Foundation and NIH.

We have recruited top talent to plan and execute on these projects within an aggressive timeline.

In the past year Vincere has received multiple awards from pharmaceutical companies such as Johnson & Johnson and Bristol Myers Squibb acknowledging the potential of our program.

Technology Platform Powers Repeatable Invention

Prioritize targets. Data: human genetics, method:
analytics.

Validate targets. Data: patient omics, method:
physics simulation.

Select molecule hits. Data: 10,000,000 molecules,
method: virtual screen.

Select patients likely to respond. Data: patient
omics, method: deep neural net.